3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Gastrointestinal
4
CNS
3
Genitourinary
2
Tumor-Agnostic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Mesothelioma
1
Lung Neoplasms
1
Interventions
Injections
98
pembrolizumab
90
Carboplatin
57
Paclitaxel
54
Cisplatin
52
Nivolumab
44
Docetaxel
43
Pemetrexed
42
Gemcitabine
37
atezolizumab
32
tislelizumab
29
Bevacizumab
29
toripalimab
23
Fluorouracil
23
Capecitabine
23
Irinotecan
22
Oxaliplatin
20
durvalumab
19
Ipilimumab
18
Leucovorin
17
Cetuximab
17
Rifampin
14
Itraconazole
14
olaparib
13
spartalizumab
12
Midazolam
12
Cyclophosphamide
12
trifluridine tipiracil drug combination
11
sintilimab
11
Drug Therapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Drug Delivery Systems
×
Other solid neoplasm
×
Clear all
NCT00748085
2015-07-23
ICEtheMAD
CSA Medical, Inc.
Phase NA
Terminated
5 enrolled
5 charts